PDF

Int J Med Sci 2024; 21(12):2272-2284. doi:10.7150/ijms.97682 This issue Cite

Research Paper

Hyperbaric oxygen therapy alleviates intestinal dysfunction following traumatic brain injury via m⁶A regulation

Xuelai Yu^1,*, Wei Zhao^2,*, Yunyun Liu^3,*, Jingchuan Lv^4, , Xiang Zhong^5, , Peizan Huang^2,

1. Department of Hyperbaric Oxygen, The Fourth Affiliated Hospital of Nanjing Medical University, 210031 Nanjing, China.
2. Department of Neurosurgery, The Fourth Affiliated Hospital of Nanjing Medical University, 210031 Nanjing, China.
3. Department of Pathology, The Fourth Affiliated Hospital of Nanjing Medical University, 210031 Nanjing, China.
4. Department of Intensive Care Unit, Nanjing Tongren Hospital, School of Medicine, Southeast University, 211102 Nanjing, China.
5. College of Animal Science and Technology, Nanjing Agricultural University, 210095 Nanjing, China.
* These authors contributed equally to this work.

✉ Corresponding authors: Jingchuan Lv, Department of Intensive Care Unit, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China; E-mail: lvjcorg. Xiang Zhong, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China; E-mail: zhongxiangedu.cn. Peizan Huang, Department of Neurosurgery, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China; E-mail: drpeizan.huangedu.cn. More

Abstract

Hyperbaric oxygen (HBO) therapy can attenuate neurological impairment after traumatic brain injury (TBI) and alleviate intestinal dysfunction. However, the role and mechanism of HBO therapy in intestinal dysfunction following TBI remain unclear. Herein, by establishing a mouse model of controlled cortical impact (CCI), we found that HBO therapy reduced histopathological lesions and decreased the levels of inflammatory and oedema proteins in the intestinal tissues of mice 10 days after TBI. We also showed that HBO therapy improved microbiome abundance and probiotic (particularly g_Bifidobacterium) colonisation in mice post-CCI. Then, we identified that the m⁶A level imcreased notably in injured cortical tissue of CCI+HBO group compared with the CCI group following CCI. Thus, our results suggested that HBO therapy could alleviate TBI-induced intestinal dysfunction and m⁶A might participate in this regulation process, which provides new insights for exploring the specific mechanism and targets of HBO in the treatment of intestinal dysfunction after TBI, thereby improving the therapeutic effect of HBO.

Keywords: hyperbaric oxygen therapy, traumatic brain injury, intestinal dysfunction, m⁶A

Introduction

Traumatic brain injury (TBI) is a major public health concern; severe brain injury develops rapidly and is the leading cause of death from trauma^[1]. Approximately 69 million TBIs occur worldwide annually ^{[2, 3]}. TBI can affect downstream communication from the brain to the gut in the brain-gut axis (BGA), including afferent and efferent signals involving crosstalk between neurones, hormones, and immunity, resulting in disorders of immune regulation, afferent nerve signals, blood-brain barrier, intestinal barrier function, digestion, and absorption^[4]. Although the number of TBI-related deaths has decreased markedly, effective therapies to promote the recovery of TBI patients are still lacking. Therefore, there has been a major shift in TBI studies regarding neural recovery^[5].

Several animal and clinical studies have shown that hyperbaric oxygen (HBO) can promote the recovery of neurological function and improve cognitive function and prognosis of TBI^[6-8]. Other studies have confirmed that HBO therapy can improve intestinal epithelial barrier dysfunction after spinal cord injury in rats^[9]. In addition, HBO treatment can ameliorate intestinal microbiota disorders after chronic stress^[10]. However, the therapeutic effect of HBO on intestinal dysfunction following TBI remains unclear, and the intervention mechanism of HBO therapy on intestinal dysfunction caused by TBI requires further exploration.

N6-methyladenosine (m⁶A) is one of the most common post-transcriptional mRNA modifications in eukaryotes and is involved in various immune and inflammatory responses^[11]. m⁶A plays an important role in both the brain and gut. The m⁶A modification regulates the activation of various nerve conduction pathways and plays a significant role in the development, differentiation, and regeneration of neurones ^[12,13]. Furthermore, m⁶A has a crucial effect on communication between the gut microbiome and the host^{[14, 15]}. In our previous study, we confirmed that YTHDF1 (one of m⁶A reading proteins) knockout could reduce TBI-induced BGA dysfunction in mice, wherein we found that YTHDF1 knockout decreased the level of inflammatory proteins in brain and intestinal tissue after TBI^[2]. However, whether m⁶A participates in HBO therapy for TBI-induced intestinal dysfunction remains elusive. To confirm the therapeutic effect of HBO on intestinal dysfunction post-TBI, we performed controlled cortical impact (CCI) in C57BL/6J mice; assigned the HBO therapy group to the intervention group; and compared differences in brain defect area and surviving neuron count in brain tissues, the ratio of villus height to crypt depth (V/C), levels of inflammation and oedema proteins in intestinal tissues, and composition of the faecal microbiome. Finally, we identified the differentially expressed levels of m⁶A to determine whether m⁶A is involved in the process of HBO therapy in TBI-induced intestinal dysfunction.

Materials and Methods

Animals and grouping

C57BL/6J male mice, aged 8-12 weeks and weighing 25±4 g, were provided by the Animal Centre of Nanjing Agricultural University (Jiangsu, China). The mice were housed in a standardised SPF animal laboratory at a constant temperature (24 °C) and humidity (50%) under a 12 h light-dark cycle and allowed free access to food and water. They were randomly divided into two groups after 1 week of acclimation: (1) CCI group (n=9) and (2) CCI + HBO group (n=9). There were no marked differences between the two groups in terms of general health, locomotor activity, reactivity, or neurological reflexes.

CCI procedure

Before inducing CCI injury, sodium pentobarbital (65 mg/kg) was injected intraperitoneally to anaesthetise the mice, and the operation was initiated once pedal reflexes were no longer present. The core body temperature was maintained at 37 °C through a heating pad during surgery. The heads of the mice were fixed in a stereotaxic frame, and a 4-mm-diameter craniotomy was performed at 2.0 mm posterior to the bregma and 2.0 mm lateral to the midline over the right hemisphere. A 3.0-mm rounded metal tip attached to the Pin-Point CCI device (Model PCI3000, Hatteras Instruments Inc., Cary, NC, USA) was angled vertically towards the brain surface. A severe injury was performed with a 2.0-mm depth, 3.0 m/s speed, and 180 ms procedural duration^[2] (Supplemental figure 1). The mice were removed from the stereotaxic holder after surgery, and the wound was lightly sutured. Body temperature was maintained in heated cages after the operation, and the mice were returned to their original cages after they were fully awake.

Hyperbaric oxygen treatment

Mice in the CCI+HBO group began receiving HBO treatment in an experimental hyperbaric chamber 4 h after surgery. The chamber was flushed with 100% O₂ for 5 min to avoid carbon dioxide accumulation. Compression to 2.5 atmospheres absolute pressure (ATA) was performed for 15 min, followed by maintaining the pressure at 2.5 ATA while inhaling 100% oxygen for 60 min. Subsequently, decompression to normobaric air was conducted for 15 min^[16,17]. In the whole process, The mice were allowed free access to food and water in the chamber. According to the above treatment regimen, mice received HBO treatment once daily for 10 consecutive days. The mice in the CCI group inhaled 21% oxygen at 1.0 ATA postoperatively.

Sample collection

One mouse died in the CCI+HBO group and three mice died in the CCI group. They were supplemented and given the same CCI and HBO treatments. Haematoxylin and eosin (HE) staining was performed on three mice in each of the two groups 10 days after CCI. Mice were euthanised via intraperitoneal injection of sodium pentobarbital (65 mg/kg) and perfused transcardially with phosphate-buffered saline, followed by 50 mL of 4% paraformaldehyde. The brains were promptly removed from the mouse body and fixed in 4% paraformaldehyde at 4 °C for 48 h. A vibratome (Leica VT 1000S, Wetzlar, Germany) was used to obtain coronal sections containing the entire hippocampus (-0 mm, -3.5 mm) relative to the bregma. A cryostat (Leica CM 1950) was used to cut serial coronal sections (30 μm thick) for HE staining (n = 3 per group). Jejunal tissue was excised, fixed in 4% paraformaldehyde solution, dehydrated using ethanol and xylene, and embedded in paraffin. In addition, 5 mm-thick sections were cut for HE staining. Furthermore, the injured cerebral cortex (respective n=6) and jejunal tissue (respective n=6) were promptly dissected, weighed, frozen in liquid nitrogen, and then stored at -80 °C for enzyme-linked immunosorbent assay (ELISA). Moreover, the faecal samples (respective n=3) were promptly collected, weighed, frozen in liquid nitrogen, and then stored at -80 °C for SMRT sequencing.

HE

Jejunal and brain sections were rinsed with dH₂O, stained with haematoxylin for 6 min, and then decolourised in acid alcohol for 1 s. Before immersion in LiCO₃, sections were rinsed with dH₂O for 3 s and counterstained with eosin for 15 s. The sections were rinsed with dH₂O and dehydrated with 95% ethyl alcohol for 2-3 minutes and 100% ethyl alcohol for 2-3 minutes. Subsequently, the sections were cleared with xylene for 2-5 min, mounted with DePeX (Thermo Fisher Scientific Inc., Waltham, MA, USA) in a fume hood, and visualized using an inverted microscope at 100× magnification (Nikon, Tokyo, Japan). Digital images were captured using a SPOT microscope camera (Diagnostic Instruments, Sterling Heights, MI, USA).

ELISA

The purified proteins were resuspended in carbonate buffer pH 9.6 at a concentration of 5 μg/ml, dispensed into 96-well polystyrene plates at a final volume of 50 μl per well, and fixed overnight at 4 °C. The plates were then blocked with phosphate-buffered saline (PBS) and 5% milk for 1 h at 22-26 °C. Next, the sera dilution was performed in PBS and 1% milk at a concentration of 1/200. Serum samples were incubated for 1 h at 37 °C. After three washes with PBS-Tween 0.05%, the cells were incubated with a secondary antibody, anti-human immunoglobulin G (IgG), coupled with peroxidase (Invitrogen Life Technologies, Frederick, MD, USA). Development was carried out using 0.4 mg/mL O-phenylenediamine dihydrochloride (OPD) in citrate buffer pH 5 with 0.024% hydrogen peroxide (H₂O₂) after additional washing with PBS-Tween 0.05%. Finally, the optical density (OD) at 450 nm was measured in a microplate reader (Mindray, Shenzhen, PR China).

RNA isolation and RNA m⁶A quantification

Total RNA was extracted using TriReagent (Sigma, T9424) according to the manufacturer's protocol. Then, the absolute amount of m⁶A present in total RNA was measured through the ELISA-based EpiQuik m⁶A RNA Methylation Quantification Kit (Epigentek, P-9005) according to the manufacturer's protocol. Quantification was performed via a Nanodrop and Bioanalyzer system (Thermo, Nanodrop 1000), and 200 ng of RNA was added to the assay wells. The m⁶A levels were quantified through measuring absorbance. Calculations were performed based on a standard curve.

PCR amplification and SMRT sequencing

Using the E.Z.N.A.® Soil DNA Kit (Omega Biotek, Norcross, GA, U.S.), total DNA was extracted from the faecal samples according to the manufacturer's protocols. The V1-V9 region of the bacterial 16S ribosomal RNA gene was amplified via PCR (95 °C for 2 min, followed by 27 cycles at 95 °C for 30 s, 55 °C for 30 s, and 72 °C for 60 s and a final extension at 72 °C for 5 min) using primers 27F 5′-AGRGTTYGATYMTGGCTCAG-3′ and 1492R 5′-RGYTACCTTGTTACGACTT-3′, where the barcode is an eight-base sequence unique to each sample. PCRs were performed in triplicate in a 20 μL mixture containing 4 μL of 5 × FastPfu Buffer, 2 μL of 2.5 mM dNTPs, 0.8 μL of each primer (5 μM), 0.4 μL of FastPfu Polymerase, and 10 ng of template DNA. Amplicons were extracted from 2% agarose gels and purified using an AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, Union City, CA, U.S.) following the manufacturer's instructions. Next, SMRTbell libraries were prepared from the amplified DNA through blunt ligation according to the manufacturer's instructions (Pacific Biosciences). Purified SMRTbell libraries from the Zymo and HMP mock communities were sequenced on dedicated PacBio Sequel II 8 M cells using the Sequencing Kit 2.0 chemistry. Finally, the purified SMRTbell libraries from the pooled and barcoded samples were sequenced on a single PacBio Sequel II cell.

Statistical analyses

All data are presented as the mean ± standard error (SE). Student's t-tests were used to evaluate the difference between two groups, and a p value < 0.05 was considered significant. All analyses were performed using SPSS version 25.0 (IBM, New York, NY, USA). Bar charts display the predominant abundant phyla and species (>1% abundance). The relative abundance was detected between sequencing technologies using a paired Student's t-test. Significant differences in taxa between the CCI and CCI+HBO groups at 10 days post-CCI were compared using linear discriminant analysis effect size (LEfSe), which employs a nonparametric factorial Kruskal-Wallis test with a subsequent unpaired Wilcoxon test. An LDA > 3 and a p value < 0.05 were considered significant. Alpha diversity (ACE, Chao, Simpson's, and Shannon indices) was compared between CCI and CCI+HBO samples using a t-test with two dependent means, and the significance level was set at p < 0.05. Principal coordinate analysis plots and clustering dendrograms were generated to visualise the beta diversity of the faecal microbiomes in the CCI and CCI+HBO groups.

Results

HBO decreases cortical tissue loss while increasing neuronal cell survival and jejunal tissue V/C ratio following CCI

Ten days after CCI, HE staining showed a marked loss of cortical tissue in the CCI group compared with that of the CCI+HBO group (Figure 1A) (p <0.05). Meanwhile, the CCI group showed a distinct decrease in the total neuron count in the perilesional zone to trauma compared to that in the CCI+HBO group (Figure 1B). In addition, villus height decreased, while crypt depth increased in the jejunal tissue, and the V/C ratio of the CCI group decreased markedly compared with that of the CCI+HBO group (Figure 1C).

HBO decreases inflammation and oedema protein level of jejunal tissue post-CCI

Ten days after CCI, ELISA analysis revealed a notable decrease in inflammatory proteins, including hypoxia-inducible factor 1-alpha (HIF-1a) and the oedema protein aquaporin 4 (AQP4), while regulatory T cells (Treg) showed a significant increase in the CCI+HBO group compared to that in the CCI group in jejunal tissue. Intriguingly, there was no marked difference in injured cortical tissue between the CCI+HBO and CCI groups (Figure 2A-C).

HBO increases microbiome abundance, and changes microbiome structure and microbiome colonization after CCI

The raw data from Illumina sequencing were processed using the QIIME2 pipeline, and their relative abundance was calculated and grouped according to mouse origin (Figure 3). The results indicated different profiles of communities in the faecal microbiomes of CCI+HBO and CCI mice 10 days after CCI. At the class level, the most abundant microbiomes in the CCI+HBO group were Clostridia (61.5%), Bacteroidia (15.8%), Erysipelotrichia (10.3%), and Bacilli (6.8%), while the CCI group microbiomes were dominated by Clostridia (62.9%), Bacteroidia (17.0%), Bacilli (7.2%), and Erysipelotrichia (2.6%). At the family level, the most abundant microbiomes in the CCI+HBO group were Lachnospiraceae (39.5%), Muribaculaceae (14.2%), and Oscillospiraceae (12.4%), while the CCI group microbiomes were dominated by Lachnospiraceae (37.7%), Oscillospiraceae (14.8%), and Muribaculaceae (13.7%). At the genus level, the most abundant microbiomes in the CCI+HBO group were Kineothrix (19.5%), Allobaculum (10.1%), Duncaniella (7.9%), and Acetatifactor (4.9%), while the CCI group microbiomes were dominated by Kineothrix (10.9%), Acetatifactor (6.9%), Duncaniella (5.4%), and Allobaculum (1.7%). At the order level, the most abundant microbiomes in the CCI+HBO group were Eubacteriales (61.5%), Bacteroidales (15.8%), Erysipelotrichales (10.3%), and Lactobacillales (6.8%), while the CCI group were dominated by Eubacteriales (62.9%), Bacteroidales (17.0%), Lactobacillales (7.1%), and Erysipelotrichales 2.6%). At the species level, the most abundant microbiomes in the CCI+HBO group were Kineothrix alysoides (19.5%), Allobaculum stercoricanis (10.1%), Acetatifactor sp900066365 (4.0%), and Duncaniella freteri (3.0%), while the CCI group microbiomes were dominated by Kineothrix alysoides (10.7%), Acetatifactor sp900066365 (5.5%), Duncaniella freteri (3.4%), and Allobaculum stercoricanis (1.7%).

For alpha diversity, the Chao1 and ACE indices indicated the abundance of the microbiome, whereas Shannon's and Simpson's indices demonstrated the diversity of the microbiome. The results showed that the Chao1 and ACE indices of faecal microbiomes in CCI+HBO mice were significantly higher than those in CCI mice at 10 days post-CCI (p < 0.05) (Figure 4A-B). However, Shannon's and Simpson's indices of faecal microbiomes in CCI+HBO and CCI mice were similar (Figure 4C-D).

The beta diversity exhibiting the community distance between samples was evaluated by unweighted and weighted UniFrac distances (Figure 5A-D), which indicated a marked difference (p < 0.05) in the microbiome profiles between the CCI+HBO and CCI groups at 10 days after CCI.

Differential taxa between CCI+HBO and CCI mice were analysed using the LefSe method. The results in Figure 6A illustrate the enriched microbiome taxa in each group that had a >2-fold change and P < 0.05 (Kruskal‒Wallis test). The faecal microbiome of the CCI+HBO mice diverged significantly from that of the CCI mice 10 days after CCI (Figure 6B), indicating diverse microbiome colonisation.

HBO increases m⁶A level in brain tissue following CCI

ELISA analysis revealed that the total m⁶A level increased markedly in the CCI+HBO group compared to that in the CCI group in injured cortical tissue 10 days after CCI. However, there was no notable difference between the CCI+HBO and CCI groups in jejunal tissue (Figure 7).

 Figure 1 

Histological images of HE coronal sections showing the brain tissue loss and neuronal survivals at 10 days post-CCI. (A) The lesion volume increased in CCI group compared to CCI+HBO group (n = 3 mice per group). Scale bars: 200 μm. The lesion volume was quantified (Calculation formula: lesion volume (%) = (healthy side volume-injured side volume) / healthy side volume × 100%). * p<0.05. (B) The neuronal survivals decreased in CCI group compared to CCI+HBO group. Scale bars: 20 μm. The number of neuronal survival (5 fields/ section) was quantified. Values are means ±SEs. * p<0.05. (C) The villus height decreased and the crypt depth increased in CCI group compared to CCI+HBO group. Scale bars: 40 μm. The V/C ratio (5 fields/ section) was quantified. Values are means ± SEs. * p<0.05.

 Figure 2 

ELISA revealed that HBO significantly affected the inflammation and edema protein level in jejunal tissue at 10 days post-CCI. (A) Compared to CCI group, the inflammation protein HIF-1a level of CCI+HBO group was decreased markedly in jejunal tissue while there was no notable difference in injured cortical tissue. (B) Compared to CCI group, the edema protein AQP4 level of CCI+HBO group was decreased significantly in jejunal tissue while there was no marked difference in injured cortical tissue. (C) Compared to CCI group, the Treg level of CCI+HBO group was increased s markedly in jejunal tissue while there was no significant difference in injured cortical tissue. Values are means ± SEs. *P < 0.05, ns = not significant.

Discussion

Several studies have focused on the role of HBO in the treatment of various neurological diseases such as stroke^[18-20], intracerebral haemorrhage^[21], glioma^[22,23], Alzheimer's disease^[24,25], Parkinson's disease^[26,27], cerebral palsy^[28,29], and TBI^[30-33]. In addition, numerous studies have confirmed that HBO therapy can improve intestinal dysfunction after spinal cord injury^[9,34] and chronic stress^[10]. However, few studies have focused on the role of HBO in intestinal dysfunction following TBI. We observed that HBO therapy reduced histopathological lesions and decreased the levels of inflammation and oedema proteins in the intestinal tissues of mice 10 days after TBI. It also improved microbiome abundance and probiotic colonisation in mice post-CCI. We found that HBO increased the level of m⁶A in injured cortical tissue, suggesting that m⁶A may be involved in the regulation of TBI recovery after HBO treatment.

After TBI, TBI-induced neuroinflammation affects gut function via BGA^[35]. Our results showed that HBO attenuated structural lesions in both brain and intestinal tissues following TBI. At the protein level, hypoxic conditions induce HIF-1a expression, which regulates the releases of inflammatory cytokines^[36]. Tregs are a special family of inhibitory CD4+T cells that act as key negative regulators of inflammation in various biological environments. Tregs show a strongly enhanced inhibitory function when exposed to inflammation^[37]. HBO therapy boosts Treg expression while reducing HIF-1α expression in mice with antigen and collagen-induced arthritis^[38]. In addition, AQP4 expression increases in TBI^[39] and colonic inflammation^[40], and AQP4-knockout attenuates experimental colitis in mice^[41]. Our results revealed that HBO blocked intestinal inflammation and oedema in mice 10 d after TBI. However, the expression of inflammatory and oedema proteins in the brain tissue was not significantly different between the CCI+HBO and CCI groups at 10 days post-TBI. We speculated that 10 days after CCI, although inflammation and oedema reactions in brain tissue had subsided without HBO treatment^[42-44], they persisted in intestinal tissue.

The gut microbiome is a rich and complex ecosystem composed of viruses, archaea, protists, bacteria, fungi, and (occasionally) helminths^[45]. Gut bacteria are critical for microbiome-BGA^[46], and the fungi equilibrium is crucial for microbiome stability^[47]. Microbiome interactions may be involved in the microbiome-BGA communication through immune- and nonimmune-modulated crosstalk systems^[48]. Substantial evidence has revealed that TBI can affect the gut microbiome by disrupting BGA^[49], and host m⁶A modifications can induce gut inflammatory responses to alter the gut microbiome^[2,50]. M⁶A could participate in the interaction between the host and microbiome, along with noncoding RNAs, histone modifications, and chromatin remodelling^[51].

 Figure 3 

The bar plots reveal the relative abundance of microbiomes in fecal samples of CCI+HBO mice and CCI mice at 10 days after CCI (A = class, B = family, C = genus, D = order, and E = species), which were detected by high throughput sequencing on Internal transcribed spacer 2 (ITS2) of ribosomal DNA and analyzed by QIIME2 pipeline.

 Figure 4 

The comparison of alpha diversity of microbiome in in fecal samples of CCI+HBO mice and CCI mice at 10 days following CCI calculated by 4 different indices: A = Chao1 index, B = ACE index, C = Shannon's index, and D = Simpson's index. The bars show average diversity with standard error of each group and statistically significant difference (*P < 0.05, ns = not significant).

In addition, HBO can remodel the gut microbiome and regulate host metabolism to improve depression-like behaviour in a chronic stress mouse model^[52]. Thus, we observed alterations in the faecal microbiome and m⁶A levels following HBO treatment for TBI. This study results indicated that the diversity of the microbiome was markedly altered in CCI+HBO and CCI mice at 10 days after CCI. In alpha diversity, the Chao1 and ACE indices of the CCI+HBO mice were significantly higher than those of the CCI mice, whereas Shannon's and Simpson's indices were similar; hence, HBO enhanced the abundance of the microbiome but not its diversity of the microbiome post-CCI. Beta diversity analysis revealed the specific microbiome structure identified in the group samples. The unweighted and weighted UniFrac distances showed that the faecal microbiomes of CCI+HBO and CCI mice had various community structures. The distinct characteristics of the microbiome can be detected from the class to the species level. The results of this study demonstrated that the microbiome composition varied between the CCI+HBO and CCI groups. Allobaculum, Kineothrix, Ruminococcus, Bifidobacterium, and Actinomycetia showed significant enrichment in CCI+HBO mice (Figure 6B). Allobaculum was one of the intestinal genera that are most sensitive to changes in host diet and was strongly inversely correlated with circulating leptin and expression of several genes that correlated with energy expenditure and inflammation^[53]. Kineothrix produces butyrate, a metabolite that serves as energy source of enterocytes and has notable anti-inflammatory and immunomodulatory properties^[54]. Ruminococcus serve to degrade and convert complex polysaccharides into a variety of nutrients for their hosts^[55]. Bifidobacterium has long been regarded as a probiotic that modulates the microbial structure to improve gut health^[56]. Actinomycetia play major roles in soil and plant health ^[57]. In addition, Allobaculum^[58], Kineothrix^[59], and Ruminococcus^[55] are strictly-anaerobic, and Bifidobacterium is obligate anaerobic^[60], while Actinomycetia is aerobic^[57]. The bacterial species dominating the microbiota in the gut are strict anaerobes^[61]. However, gut inflammation can induce dysbiosis, which is characterized by significantly decreased obligate anaerobic bacteria and markedly increased facultative anaerobic bacteria^[62]. Dysbiosis is the result of the oxidative nature of the host inflammatory response^[63]. In addition, the composition of the gut microbiota is regulated by the oxygen^[64]. Yong Li et al. found in a study on hyperbaric oxygen treatment for Crohn's disease that the relative abundance of Bifidobacterium increased after HBO treatment while the anaerobic or aerobic nature of microbes did not represent the trend of the population in their host after HBO treatment^[65]. HBO can modulate mitochondrial redox, maintain mitochondrial integrity, catalyze transcription factors, alleviate oxidative stress, and facilitate anti-inflammatory effects following TBI^[66], which may improve post-TBI dysbiosis. The interactions between the gut microbiota and host during the process of HBO treatment after TBI should be further clarified.

 Figure 5 

The beta diversity of faecal microbiome between samples was showed by principle coordinate analysis (PCoA) and non-metric multidimensional scaling (NMDS) plots of A+C unweighted and B+D weighted Unifrac distance illustrating marked difference of faecal microbiome profiles between CCI+HBO and CCI groups (tested by Permanova analysis with P < 0.05).

 Figure 6 

LEfSe analysis of fecal microbiome of mice at 10 days after CCI shows the significantly differential taxa between CCI+HBO and CCI mice. A Cladogram (2-fold, P < 0.05). B LEfSe analysis for differential abundant taxa detected between CCI+HBO and CCI groups. Threshold parameters were set as P =0.05 for the Mann-Whitney U test and multiclass analysis=all against all. Linear discriminant analysis (LDA) score >3.0. (Green color labels demonstrate the enriched fungal taxa in CCI+HBO while the red labels indicate the taxa enriched in CCI group.

 Figure 7 

ELISA showed that HBO notably affected the m⁶A level in injured cortical tissue while there was no marked difference in jejunal tissue at 10 days after CCI.Values are means ± SEs. *P < 0.05, ns = not significant.

Moreover, m⁶A RNA modification is an important mechanism in the interaction between the gut microbiota and the host^[67]. Bifidobacterium and Lactobacillus species can synthesise folate to enhance gut m⁶A levels, which promotes normal gut development^[56]. In this study, the results showed that the m⁶A level increased notably in the injured cortical tissue of the CCI+HBO group compared to that in the CCI group, but there was no significant difference in jejunal tissue between the CCI+HBO and CCI groups at 10 days after CCI (Figure 7). Therefore, we speculated that HBO therapy might alleviate TBI-induced intestinal dysfunction via m⁶A-mediated BGA signalling pathway.

Conclusion

Our study provides new insights into HBO treatment for TBI-induced intestinal dysfunction. Further studies are necessary to explore the mechanisms of m⁶A involved in HBO curing intestinal dysfunction following TBI. This study had several limitations. Firstly, the expression of inflammation and oedema proteins between the CCI+HBO and CCI groups in the brain tissue was not markedly different at 10 days following TBI; therefore, a suitable sampling time point is required. Secondly, we only described the alteration of total m⁶A levels between the CCI+HBO and CCI groups after TBI; changes in the specific gene levels of m⁶A between the CCI+HBO and CCI groups remain to be explored in future studies. Thirdly, our study only included male mice, and data from female mice should be collected. In summary, HBO therapy could alleviate TBI-induced intestinal dysfunction, and m⁶A might play a role in the regulatory mechanisms of HBO treatment for intestinal dysfunction following TBI.

Supplementary Material

Supplementary figure.

Acknowledgements

This work was supported by grants from the Talent research project of the Fourth Affiliated Hospital of Nanjing Medical University (to Peizan Huang).

Institutional review board statement

All protocols of animal experiments were approved by the Animal Ethics Committee of Nanjing Agricultural University (SYXK 2021-0086) and complied with the guidelines of Use and Care of Experimental Animals of Nanjing Agricultural University.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Esterov D, Bellamkonda E, Mandrekar J, Ransom JE, Brown AW. Cause of Death after Traumatic Brain Injury: A Population-Based Health Record Review Analysis Referenced for Nonhead Trauma. Neuroepidemiology. 2021;55(3):180-187

2. Huang P, Liu M, Zhang J, Zhong X, Zhong C. YTHDF1 Attenuates TBI-Induced Brain-Gut Axis Dysfunction in Mice. Int J Mol Sci. 2023Feb20;24(4):4240

3. Dewan MC. et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018;130:1080-1097

4. Dabrowski W, Siwicka-Gieroba D, Kotfis K, Zaid S, Terpilowska S, Robba C, Siwicki AK. The Brain-gut Axis-where are we now and how can we Modulate these Connections? Curr Neuropharmacol. 2021;19(8):1164-1177

5. Moschonas EH, Ranellone TS, Vozzella VJ, Rennerfeldt PL, Bondi CO, Annas EM, Bittner RA, Tamura DM, Reddy RI, Eleti RR, Cheng JP, Jarvis JM, Fink EL, Kline AE. Efficacy of a music-based intervention in a preclinical model of traumatic brain injury: An initial foray into a novel and non-pharmacological rehabilitative therapy. Exp Neurol. 2023Nov;369:114544

6. Lu Y, Zhou X, Cheng J, Ma Q. Early Intensified Rehabilitation Training with Hyperbaric Oxygen Therapy Improves Functional Disorders and Prognosis of Patients with Traumatic Brain Injury. Adv Wound Care (New Rochelle). 2021Dec;10(12):663-670

7. Jeremic R, Pekovic S, Lavrnja I, Bjelobaba I, Djelic M, Dacic S, Brkic P. Hyperbaric Oxygenation Prevents Loss of Immature Neurons in the Adult Hippocampal Dentate Gyrus Following Brain Injury. Int J Mol Sci. 2023Feb21;24(5):4261

8. Sakas R, Dan K, Edelman D, Abu-Ata S, Ben-Menashe A, Awad-Igbaria Y, Francois-Soustiel J, Palzur E. Hyperbaric Oxygen Therapy Alleviates Memory and Motor Impairments Following Traumatic Brain Injury via the Modulation of Mitochondrial-Dysfunction-Induced Neuronal Apoptosis in Rats. Antioxidants (Basel). 2023Nov23;12(12):2034

9. Liu X, Liang F, Zhang J, Li Z, Yang J, Kang N. Hyperbaric Oxygen Treatment Improves Intestinal Barrier Function After Spinal Cord Injury in Rats. Front Neurol. 2020Oct15;11:563281

10. Zhang B, Dong W, Ma Z, Duan S, Han R, Lv Z, Liu X, Mao Y. Hyperbaric oxygen improves depression-like behaviors in chronic stress model mice by remodeling gut microbiota and regulating host metabolism. CNS Neurosci Ther. 2023Jan;29(1):239-255

11. Leoni C, Bataclan M, Ito-Kureha T, Heissmeyer V, Monticelli S. The mRNA methyltransferase Mettl3 modulates cytokine mRNA stability and limits functional responses in mast cells. Nat Commun. 2023Jun29;14(1):3862

12. Zou Z, Wei J, Chen Y, Kang Y, Shi H, Yang F, Shi Z, Chen S, Zhou Y, Sepich-Poore C, Zhuang X, Zhou X, Jiang H, Wen Z, Jin P, Luo C, He C. FMRP phosphorylation modulates neuronal translation through YTHDF1. Mol Cell. 2023Dec7;83(23):4304-4317.e8

13. Zhao Y, Li J, Lian Y, Zhou Q, Wu Y, Kang J. METTL3-Dependent N6-Methyladenosine Modification Programs Human Neural Progenitor Cell Proliferation. Int J Mol Sci. 2023Oct24;24(21):15535

14. Su H, Cheung H, Lau HC, Chen H, Zhang X, Qin N, Wang Y, Chan MTV, Wu WKK, Chen H. Crosstalk between gut microbiota and RNA N6-methyladenosine modification in cancer. FEMS Microbiol Rev. 2023Jul5;47(4):fuad036

15. Zhuo R. et al. The regulatory role of N(6) -methyladenosine modification in the interaction between host and microbes. Wiley Interdiscip Rev RNA. 2022: e1725.

16. Fachi JL, Pral LP, Assis HC, Oliveira S, Rodovalho VR, Dos Santos JAC, Fernandes MF, Matheus VA, Sesti-Costa R, Basso PJ, Flóro E Silva M, Câmara NOS, Giorgio S, Colonna M, Vinolo MAR. Hyperbaric oxygen augments susceptibility to C. difficile infection by impairing gut microbiota ability to stimulate the HIF-1α-IL-22 axis in ILC3. Gut Microbes. 2024;16(1):2297872

17. Akin ML, Uluutku H, Erenoglu C, Ilicak EN, Elbuken E, Erdemoglu A, Celenk T. Hyperbaric oxygen ameliorates bacterial translocation in rats with mechanical intestinal obstruction. Dis Colon Rectum. 2002Jul;45(7):967-72

18. Hadanny A, Rittblat M, Bitterman M, May-Raz I, Suzin G, Boussi-Gross R, Zemel Y, Bechor Y, Catalogna M, Efrati S. Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients - a retrospective analysis. Restor Neurol Neurosci. 2020;38(1):93-107

19. Wang SD, Fu YY, Han XY, Yong ZJ, Li Q, Hu Z, Liu ZG. Hyperbaric Oxygen Preconditioning Protects Against Cerebral Ischemia/Reperfusion Injury by Inhibiting Mitochondrial Apoptosis and Energy Metabolism Disturbance. Neurochem Res. 2021Apr;46(4):866-877

20. Thiankhaw K, Chattipakorn N, Chattipakorn SC. The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion. J Cell Physiol. 2021Mar;236(3):1677-1694

21. Wang BQ, He M, Wang Y, Liu S, Guo ZW, Liu ZL. Hyperbaric oxygen ameliorates neuronal injury and neurological function recovery in rats with intracerebral hemorrhage by silencing microRNA-204-5p-targeted chloride channel protein 3. J Physiol Pharmacol. 2023 Jun;74(3)

22. Wang WJ, Ding JS, Sun Q, Xu X, Chen G. Role of hyperbaric oxygen in glioma: a narrative review. Med Gas Res. 2022;12(1):1-5

23. Zeng X, Wang Q, Tan X, Jia L, Li Y, Hu M, Zhang Z, Bai X, Zhu Y, Yang X. Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma. J Nanobiotechnology. 2019Apr1;17(1):47

24. Shapira R, Gdalyahu A, Gottfried I, Sasson E, Hadanny A, Efrati S, Blinder P, Ashery U. Hyperbaric oxygen therapy alleviates vascular dysfunction and amyloid burden in an Alzheimer's disease mouse model and in elderly patients. Aging (Albany NY). 2021Sep9;13(17):20935-20961

25. Chen J, Zhang F, Zhao L, Cheng C, Zhong R, Dong C, Le W. Hyperbaric oxygen ameliorates cognitive impairment in patients with Alzheimer's disease and amnestic mild cognitive impairment. Alzheimers Dement (N Y). 2020Jun14;6(1):e12030

26. Hsu HT, Yang YL, Chang WH, Fang WY, Huang SH, Chou SH, Lo YC. Hyperbaric Oxygen Therapy Improves Parkinson's Disease by Promoting Mitochondrial Biogenesis via the SIRT-1/PGC-1α Pathway. Biomolecules. 2022Apr30;12(5):661

27. Xu JJ, Yang ST, Sha Y, Ge YY, Wang JM. Hyperbaric oxygen treatment for Parkinson's disease with severe depression and anxiety: A case report. Medicine (Baltimore). 2018Mar;97(9):e0029

28. Laureau J, Pons C, Letellier G, Gross R. Hyperbaric oxygen in children with cerebral palsy: A systematic review of effectiveness and safety. PLoS One. 2022Oct14;17(10):e0276126

29. Zhang Y, Wu J, Xiao N, Li B. Hyperbaric Oxygen Therapy Is Beneficial for the Improvement of Clinical Symptoms of Cerebral Palsy: A Systematic Review and Meta-Analysis. Complement Med Res. 2022;29(2):158-171 English

30. Jiang Y, Chen Y, Huang C, Xia A, Wang G, Liu S. Hyperbaric oxygen therapy improves neurological function via the p38-MAPK/CCL2 signaling pathway following traumatic brain injury. Neuroreport. 2021Oct13;32(15):1255-1262

31. Hadanny A, Catalogna M, Yaniv S, Stolar O, Rothstein L, Shabi A, Suzin G, Sasson E, Lang E, Finci S, Polak N, Fishlev G, Harpaz RT, Adler M, Goldman RE, Zemel Y, Bechor Y, Efrati S. Hyperbaric oxygen therapy in children with post-concussion syndrome improves cognitive and behavioral function: a randomized controlled trial. Sci Rep. 2022Sep23;12(1):15233

32. Miskin BM, Fox LA, Abou-Al-Shaar H, Bin-Alamer O, Goertz A, Lipin CT, Fertig N, Cox N. Hyperbaric Oxygen Therapy for the Management of Mild and Moderate Traumatic Brain Injury: A Single-Center Experience. World Neurosurg. 2023Aug;176:e357-e370

33. Otsuka Y, Tomura S, Toyooka T, Takeuchi S, Tomiyama A, Omura T, Saito D, Wada K. Hyperbaric hydrogen therapy improves secondary brain injury after head trauma. Undersea Hyperb Med. 2023;50(4):403-411

34. Liu X, Liang F, Song W, Diao X, Zhu W, Yang J. Effect of Nrf2 signaling pathway on the improvement of intestinal epithelial barrier dysfunction by hyperbaric oxygen treatment after spinal cord injury. Cell Stress Chaperones. 2021Mar;26(2):433-441

35. Hanscom M, Loane DJ, Shea-Donohue T. Brain-gut axis dysfunction in the pathogenesis of traumatic brain injury. J Clin Invest. 2021Jun15;131(12):e143777

36. Jeong HJ, Chung HS, Lee BR, Kim SJ, Yoo SJ, Hong SH, Kim HM. Expression of proinflammatory cytokines via HIF-1alpha and NF-kappaB activation on desferrioxamine-stimulated HMC-1 cells. Biochem Biophys Res Commun. 2003Jul11;306(4):805-11

37. van der Veeken J, Gonzalez AJ, Cho H, Arvey A, Hemmers S, Leslie CS, Rudensky AY. Memory of Inflammation in Regulatory T Cells. Cell. 2016Aug11;166(4):977-990

38. Harnanik T, Soeroso J, Suryokusumo MG, Juliandhy T. Effects of Hyperbaric Oxygen on T helper 17/regulatory T Polarization in Antigen and Collagen-induced Arthritis: Hypoxia-inducible Factor-1α as a Target. Oman Med J. 2020Jan23;35(1):e90

39. Dadgostar E, Rahimi S, Nikmanzar S, Nazemi S, Naderi Taheri M, Alibolandi Z, Aschner M, Mirzaei H, Tamtaji OR. Aquaporin 4 in Traumatic Brain Injury: From Molecular Pathways to Therapeutic Target. Neurochem Res. 2022Apr;47(4):860-871

40. Meli R, Pirozzi C, Pelagalli A. New Perspectives on the Potential Role of Aquaporins (AQPs) in the Physiology of Inflammation. Front Physiol. 2018Feb16;9:101

41. Wang L, Tang H, Wang C, Hu Y, Wang S, Shen L. Aquaporin 4 deficiency alleviates experimental colitis in mice. FASEB J. 2019Aug;33(8):8935-8944

42. Donkin JJ, Vink R. Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Curr Opin Neurol. 2010Jun;23(3):293-9

43. Ding JY, Kreipke CW, Speirs SL, Schafer P, Schafer S, Rafols JA. Hypoxia-inducible factor-1alpha signaling in aquaporin upregulation after traumatic brain injury. Neurosci Lett. 2009Mar27;453(1):68-72

44. Yu Y, Cao F, Ran Q, Sun X. Regulatory T cells exhibit neuroprotective effect in a mouse model of traumatic brain injury. Mol Med Rep. 2016 Dec;14(6):5556-5566. doi: 10.3892/mmr.2016.5954. Epub 2016 Nov 18. Retraction in: Mol Med Rep. 2017May;15(5):2897

45. Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. Nat Rev Microbiol. 2023Dec;21(12):772-788

46. Bicknell B, Liebert A, Borody T, Herkes G, McLachlan C, Kiat H. Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome. Int J Mol Sci. 2023May31;24(11):9577

47. Lai S, Yan Y, Pu Y, Lin S, Qiu JG, Jiang BH, Keller MI, Wang M, Bork P, Chen WH, Zheng Y, Zhao XM. Enterotypes of the human gut mycobiome. Microbiome. 2023Aug11;11(1):179

48. Belvoncikova P, Splichalova P, Videnska P, Gardlik R. The Human Mycobiome: Colonization, Composition and the Role in Health and Disease. J Fungi (Basel). 2022Oct4;8(10):1046 doi: 10.3390/jof8101046

49. Kumaria A, Kirkman MA, Scott RA, Dow GR, Leggate AJ, Macarthur DC, Ingale HA, Smith SJ, Basu S. A Reappraisal of the Pathophysiology of Cushing Ulcer: A Narrative Review. J Neurosurg Anesthesiol. 2023;36:211-217

50. Zong X. et al. Mettl3 Deficiency Sustains Long-Chain Fatty Acid Absorption through Suppressing Traf6-Dependent Inflammation Response. J Immunol. 2019;202:567-578

51. Zhuo R. et al. The regulatory role of N(6)-methyladenosine modification in the interaction between host and microbes. Wiley Interdiscip Rev. RNA. 2022;13:e1725

52. Lim SW, Sung KC, Shiue YL, Wang CC, Chio CC, Kuo JR. Hyperbaric Oxygen Effects on Depression-Like Behavior and Neuroinflammation in Traumatic Brain Injury Rats. World Neurosurg. 2017Apr;100:128-137

53. Koay YC, Wali JA, Luk AWS, Macia L, Cogger VC, Pulpitel TJ, Wahl D, Solon-Biet SM, Holmes A, Simpson SJ, O'Sullivan JF. Ingestion of resistant starch by mice markedly increases microbiome-derived metabolites. FASEB J. 2019Jul;33(7):8033-8042

54. Betts EL, Hoque S, Torbe L, Bailey JR, Ryan H, Toller K, Breakell V, Carpenter AI, Diana A, Matechou E, Gentekaki E, Tsaousis AD. Parasites, Drugs and Captivity: Blastocystis-Microbiome Associations in Captive Water Voles. Biology (Basel). 2021May22;10(6):457

55. La Reau AJ, Suen G. The Ruminococci: key symbionts of the gut ecosystem. J Microbiol. 2018Mar;56(3):199-208

56. Wu J, Zhao Y, Wang X, Kong L, Johnston LJ, Lu L, Ma X. Dietary nutrients shape gut microbes and intestinal mucosa via epigenetic modifications. Crit Rev Food Sci Nutr. 2022;62(3):783-797

57. Bhatti AA, Haq S, Bhat RA. Actinomycetes benefaction role in soil and plant health. Microb Pathog. 2017Oct;111:458-467

58. van Muijlwijk GH, Rice TA, Flavell RA, Palm NW, de Zoete MR. Allobaculum mucilyticum sp. nov. and Allobaculum fili sp. nov, isolated from the human intestinal tract. Int J Syst Evol Microbiol. 2023 Feb;73(1)

59. Haas KN, Blanchard JL. Kineothrix alysoides, gen. nov, sp. nov, a saccharolytic butyrate-producer within the family Lachnospiraceae. Int J Syst Evol Microbiol. 2017Feb;67(2):402-410

60. Dróżdż M, Makuch S, Cieniuch G, Woźniak M, Ziółkowski P. Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications. Life Sci. 2020Nov15;261:118296

61. Winter SE, Lopez CA, Bäumler AJ. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep. 2013Apr;14(4):319-27

62. Peterson DA, Frank DN, Pace NR, Gordon JI. Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell Host Microbe. 2008Jun12;3(6):417-27

63. Zhang Y, Mu T, Deng X, Guo R, Xia B, Jiang L, Wu Z, Liu M. New Insights of Biological Functions of Natural Polyphenols in Inflammatory Intestinal Diseases. Int J Mol Sci. 2023May31;24(11):9581

64. Albenberg L, Esipova TV, Judge CP, Bittinger K, Chen J, Laughlin A, Grunberg S, Baldassano RN, Lewis JD, Li H, Thom SR, Bushman FD, Vinogradov SA, Wu GD. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology. 2014Nov;147(5):1055-63.e8

65. Li Y, Sun R, Lai C, Liu K, Yang H, Peng Z, Xu D, Huang F, Tang K, Peng Y, Liu X. Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn's disease. J Transl Med. 2024May30;22(1):518

66. Hiebert JB, Shen Q, Thimmesch AR, Pierce JD. Traumatic brain injury and mitochondrial dysfunction. Am J Med Sci. 2015Aug;350(2):132-8

67. Wu J, Frazier K, Zhang J, Gan Z, Wang T, Zhong X. Emerging role of m6 A RNA methylation in nutritional physiology and metabolism. Obes Rev. 2020Jan;21(1):e12942

Author contact

Corresponding authors: Jingchuan Lv, Department of Intensive Care Unit, Nanjing Tongren Hospital, School of Medicine, Southeast University, Nanjing, China; E-mail: lvjcorg. Xiang Zhong, College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, China; E-mail: zhongxiangedu.cn. Peizan Huang, Department of Neurosurgery, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China; E-mail: drpeizan.huangedu.cn.

Received 2024-4-23
Accepted 2024-8-4
Published 2024-8-19

Citation styles

©2024 Ivyspring International Publisher. Terms of use